| 1 | Tang CY, Hang JF, Hung YP, Chiu NC, Lai JI, Chen MH, Liu CY, Yang MH, Chao Y, Chang PM. A generational comparison for unfavorable cancer of unknown primary in a single institute over 20 years Cancer Med Jan 1. IF:4 / Ranking:ONCOLOGY 96/241 |
| 2 | Lee TL, Chen TH, Kuo YJ, Lan HY, Yang MH, Chu PY. Tumor-associated tissue eosinophilia promotes angiogenesis and metastasis in head and neck squamous cell carcinoma Neoplasia Jan 1. IF:4.8 / Ranking:ONCOLOGY 80/241 |
| 3 | Chung SY, Chang YC, Hsu DS, Hung YC, Lu ML, Hung YP, Chiang NJ, Yeh CN, Hsiao M, Soong J, Su Y, Chen MH. A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer Neoplasia Jan 1. IF:4.8 / Ranking:ONCOLOGY 80/241 |
| 4 | Chen MC, Su HY, Su YH, Huang KH, Fang WL, Lin CW, Chen MH, Chao Y, Lo SS, Fen-Yau Li A, Wu CW. The clinicopathological and genetic differences among gastric cancer patients with no recurrence, early recurrence, and late recurrence after curative surgery J Chin Med Assoc Jan 1. IF:3 / Ranking:MEDICINE, GENERAL & INTERNAL 75/167 |
| 5 | Rau KM, Shun SC, Hung SH, Chou HL, Ho CL, Chao TC, Liu CY, Lien CT, Hong MY, Wu CJ, Tsai LY, Jane SW, Hsieh RK. Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment Jpn J Clin Oncol Jan 6. IF:2.4 / Ranking:ONCOLOGY 189/241 |
| 6 | Wu WC, Chen MH. Case report: Acquired neurotrophic tyrosine receptor kinase inhibitor resistance in a patient with pancreatic neuroendocrine carcinoma receiving entrectinib Front Oncol Jan 10. IF:4.7 / Ranking:ONCOLOGY 85/241 |
| 7 | Chiang NJ, Chen LT. Adjuvant therapy in biliary tract cancers: oral fluoropyrimidine as a beginning Lancet Jan 21. IF:168.9 / Ranking:MEDICINE, GENERAL & INTERNAL 1/167 |
| 8 | Su YY, Chiang NJ, Chang JS, Wang YW, Shen BN, Li YJ, Hwang DY, Shan YS, Chen LT. The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan ESMO Open Feb 1. IF:7.3 / Ranking:ONCOLOGY 45/241 |
| 9 | Wu WC, Huang CC, Tsai YF, Lin YS, Feng CJ, Chen YJ, Lai JI, Chao TC, Liu CY, Tseng LM. The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: a population-based propensity score matching and competing risk model analysis Breast Cancer Res Treat Feb 1. IF:3.8 / Ranking:ONCOLOGY 109/241 |
| 10 | Su YY, Chiang NJ, Yang YH, Yen CJ, Bai LY, Chiu CF, Chuang SC, Yang SH, Chou WC, Chen JS, Chiu TJ, Chen YY, Chan DC, Peng CM, Chiu SC, Li CP, Shan YS, Chen LT. Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer Cancers (Basel) Feb 5. IF:5.2 / Ranking:ONCOLOGY 72/241 |
| 11 | Kung CY, Fang WL, Hung YP, Huang KH, Chen MH, Chao Y, Lin SC, Li AF, Lo SS, Wu CW. Comparison of the mutation patterns between tumor tissue and cell-free DNA in stage IV gastric cancer Aging (Albany NY) Feb 10. IF:5.2 / Ranking:CELL BIOLOGY 73/191 ; GERIATRICS & GERONTOLOGY 17/54 |
| 12 | Merle P, Kudo M, Edeline J, Bouattour M, Cheng AL, Chan SL, Yau T, Garrido M, Knox J, Daniele B, Breder V, Lim HY, Ogasawara S, Cattan S, Chao Y, Siegel AB, Martinez-Forero I, Wei Z, Liu CC, Finn RS. Pembrolizumab as Second-Line Therapy for Advanced Hepatocellular Carcinoma: Longer Term Follow-Up from the Phase 3 KEYNOTE-240 Trial Liver Cancer Feb 14. IF:13.8 / Ranking:GASTROENTEROLOGY & HEPATOLOGY 7/93; ONCOLOGY 18/241 |
| 13 | Chen MC, Su HY, Su YH, Huang KH, Fang WL, Lin CW, Chen MH, Chao Y, Lo SS, FenYau Li A, Wu CW. Reply to “Is it possible that advanced-stage gastric cancer patients can be cured by surgery alone?” Journal of the Chinese Medical Association Mar 1. IF:3 / Ranking:MEDICINE, GENERAL & INTERNAL 75/167 |
| 14 | Chueh CH, Tsai YW, Chen ZR, Shiu MN, Wen YW, Chiang NJ. Cost-Effectiveness Analysis of a New Second-Line Treatment Regimen for Advanced Intrahepatic Cholangiocarcinoma: Biomarker-Driven Targeted Therapy of Pemigatinib Versus 5-FU Chemotherapy Pharmacoeconomics Mar 1. IF:4.4 / Ranking:ECONOMICS 71/380 ; HEALTH CARE SCIENCES & SERVICES 23/105 ; HEALTH POLICY & SERVICES 12/87 ; PHARMACOLOGY & PHARMACY 82/277 |
| 15 | Shao YY, Ho CL, Chang CS, Chang CL, Lee JK, Lin HJ, Hsiao HH, Chao TC, Lin CY, Liaw CC. Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants Acta Cardiol Sin Mar 1. IF:1.9 / Ranking:CARDIAC & CARDIOVASCULAR SYSTEMS 108/142 |
| 16 | Lin TY, Lee TL, Hsu YB, Tai SK, Wang LW, Yang MH, Chu PY. Survival analyses of different treatment modalities and clinical stage for hypopharyngeal carcinoma Front Oncol Mar 3. IF:4.7 / Ranking:ONCOLOGY 85/241 |
| 17 | Satake H, Lee KW, Chung HC, Lee J, Yamaguchi K, Chen JS, Yoshikawa T, Amagai K, Yeh KH, Goto M, Chao Y, Lam KO, Han SR, Shiratori S, Shah S, Shitara K. Pembrolizumab or pembrolizumab plus chemotherapy versus standard of care chemotherapy in patients with advanced gastric or gastroesophageal junction adenocarcinoma: Asian subgroup analysis of KEYNOTE-062 Jpn J Clin Oncol Mar 7. IF:2.4 / Ranking:ONCOLOGY 189/241 |
| 18 | Pan LH, Yen CC, Huang CJ, Ng XN, Lin LY. Prognostic predictors of adrenocortical carcinoma: A single-center thirty-year experience Front Endocrinol (Lausanne) Mar 10. IF:5.2 / Ranking:ENDOCRINOLOGY & METABOLISM 36/145 |
| 19 | Yang YF, Tsai KW, Chang PM, Chang YC. Editorial: Metabolism-based omics integrations, biosensors, and molecular mechanisms in human cancers Front Oncol Mar 16. IF:4.7 / Ranking:ONCOLOGY 85/241 |
| 20 | Zheng ZR, Ku HY, Chen KC, Chiang CJ, Wang CL, Chen CY, Tsai CM, Huang MS, Yu CJ, Chen JS, Chou TY, Lee WC, Wang CC, Liu TW, Hsia JY, Chang GC. Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naive ALK-positive advanced lung adenocarcinoma Front Oncol Mar 17. IF:4.7 / Ranking:ONCOLOGY 85/241 |
| 21 | Chen MC, Su HY, Su YH, Huang KH, Fang WL, Lin CW, Chen MH, Chao Y, Lo SS, Li AF, Wu CW. Reply to "Can one outcome be used to predict the other outcome?" J Chin Med Assoc Apr 1. IF:3 / Ranking:MEDICINE, GENERAL & INTERNAL 75/167 |
| 22 | Chen TH, Chen MH, Hung YP, Chiang NJ, Huang KH, Lin YH, Lin RW, Chao Y, Li AF, Yu HY, Hwang HE, Yeh YC, Wang YC, Fang WL. Elevated PD-L1 Expression and Microsatellite Instability in Elderly Patients With Gastric Cancer J Immunother Apr 1. IF:3.9 / Ranking:IMMUNOLOGY 93/161; MEDICINE, RESEARCH & EXPERIMENTAL 70/136 ; ONCOLOGY 103/241 |
| 23 | Chiu YN, Hsu CY, Lien PJ, Chao TC, Liu CY, Lin YS, Wang YL, Tsai YF, Tseng LM. Impacts of HER2 immunohistochemical scores on response and outcomes of HER2-positive breast cancers after neoadjuvant therapy J Chin Med Assoc Apr 1. IF:3 / Ranking:MEDICINE, GENERAL & INTERNAL 75/167 |
| 24 | Chen SC. Challenges in translating clinical guidelines into real-life practice for management of hepatocellular carcinoma in Taiwan Clin Mol Hepatol Apr 29. IF:8.9 / Ranking:GASTROENTEROLOGY & HEPATOLOGY 12/93 |
| 25 | Chung CH, Lin CY, Chen CY, Hsueh CW, Chang YW, Wang CC, Chu PY, Tai SK, Yang MH. Ferroptosis Signature Shapes the Immune Profiles to Enhance the Response to Immune Checkpoint Inhibitors in Head and Neck Cancer Adv Sci (Weinh) May 1. IF:15.1 / Ranking:CHEMISTRY, MULTIDISCIPLINARY 16/178; MATERIALS SCIENCE, MULTIDISCIPLINARY 24/342; NANOSCIENCE & NANOTECHNOLOGY 14/107 |
| 26 | Wang SF, Lin YS, Yeh WY, Chang YL, Chiang CE, Chen CH, Tseng LM, Lee HC, Liu CY, Cheng HM. The Clinical Benefits of Antiresorptive Agents in Primary Breast Cancer Patients Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis J Clin Endocrinol Metab May 12. IF:5.8 / Ranking:ENDOCRINOLOGY & METABOLISM 31/145 |
| 27 | Mienda BS, Cheng C-T, Lai J-M, Chang PM-H, Hong Y-R, Huang C-YF, Wang F-S. Identifying essential genes in genome-scale metabolic models of consensus molecular subtypes of colorectal cancer Plos One May 19. IF:3.7 / Ranking:MULTIDISCIPLINARY SCIENCES 26/73 ; BIOLOGY N/A |
| 28 | Pan YR, Wu CE, Jung SM, Huang SC, Lin SH, Chou WC, Chang YC, Chen MH, Hung TH, Yu AL, Huang WK, Yeh CN. Mucin 4 Confers Gemcitabine Resistance and an Unfavorable Prognosis in Patients with Cholangiocarcinoma via AKT Activation Int J Biol Sci May 21. IF:9.2 / Ranking:BIOCHEMISTRY & MOLECULAR BIOLOGY 31/285 |
| 29 | Su SP, Lee YC, Lin SL, Li YX, Lin MY, Chan YH, Lee YJ, Yang MH, Chiang HK. Realization of NIR-II 3D whole-body contour and tumor blood vessels imaging in small animals using rotational stereo vision technique J Biomed Opt May 24. IF:3.5 / Ranking:BIOCHEMICAL RESEARCH METHODS 22/77; OPTICS 34/100; RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 38/135 |
| 30 | Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations J Clin Oncol Jun 1. IF:45.3 / Ranking:ONCOLOGY 7/241 |
| 31 | Wu CH, Lai CL, Teng CJ, Fang WL, Huang KH, Fen-Yau Li A, Yu HY, Chiang NJ, Chao Y, Hung YP, Chen MH. Immunoprofile of adenosquamous carcinoma in gastric cancer J Chin Med Assoc Jun 1. IF:3 / Ranking:MEDICINE, GENERAL & INTERNAL 75/167 |
| 32 | Su YY, Chao YJ, Wang CJ, Liao TK, Su PJ, Huang CJ, Chiang NJ, Yu YT, Tsai HM, Chen LT, Shan YS. The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study Int J Surg Jun 8. IF:15.3 / Ranking:SURGERY 2/212 |
| 33 | Liu YW, Lee JY, Wang YK, Chen YH, Fang PT, Chou SH, Chen MH, Bai LY, Yen CJ, Wu MT, Wu IC. Comparison of therapeutic outcomes in esophageal squamous cell carcinoma following neoadjuvant chemoradiotherapy: A prospective observational cohort study J Formos Med Assoc Jun 27. IF:3.2 / Ranking:MEDICINE, GENERAL & INTERNAL 69/167 |
| 34 | Lin ZH, Yeh H, Lo HC, Hua WJ, Ni MY, Wang LK, Chang TT, Yang MH, Lin TY. GMI, a fungal immunomodulatory protein, ameliorates SARS-CoV-2 envelope protein-induced inflammation in macrophages via inhibition of MAPK pathway Int J Biol Macromol Jun 30. IF:8.2 / Ranking:BIOCHEMISTRY & MOLECULAR BIOLOGY 35/285; CHEMISTRY, APPLIED 7/72; POLYMER SCIENCE 5/86 |
| 35 | Fu CC, Wei CY, Chu CJ, Lee PC, Huo TI, Huang YH, Chao Y, Hou MC, Wu JC, Su CW. The outcomes and prognostic factors of patients with hepatocellular carcinoma and normal serum alpha fetoprotein levels J Formos Med Assoc Jul 1. IF:3.2 / Ranking:MEDICINE, GENERAL & INTERNAL 69/167 |
| 36 | Dai MS, Chao TC, Chiu CF, Lu YS, Shiah HS, Jackson C, Hung N, Zhi J, Cutler DL, Kwan R, Kramer D, Chan WK, Qin A, Tseng KC, Hung CT, Chao TY. Oral paclitaxel and encequidar in patients with breast cancer: a pharmacokinetic, safety, and antitumor activity study Ther Adv Med Oncol Jul 21. IF:4.9 / Ranking:ONCOLOGY 78/241 |
| 37 | Tseng CW, Teng HW, Lin CC, Lei HJ, Hung JJ, Liang WY, Hsia CY, Chou SC, Lin HH, Huang SC, Cheng HH, Lan YT, Wang HS, Yang SH, Chen WS, Lin JK, Jiang JK, Chang SC, Chau GY. Surgical strategy for colorectal cancer with synchronous liver and extrahepatic metastases: A scoring system and decision tree model J Chin Med Assoc Aug 1. IF:3 / Ranking:MEDICINE, GENERAL & INTERNAL 75/167 |
| 38 | Tseng LM, Lau KY, Chen JL, Chu PY, Huang TT, Lee CH, Wang WL, Chang YY, Huang CT, Huang CC, Chao TC, Tsai YF, Lai JI, Dai MS, Liu CY. Regorafenib induces damage-associated molecular patterns, cancer cell death and immune modulatory effects in a murine triple negative breast cancer model Exp Cell Res Aug 1. IF:3.7 / Ranking:CELL BIOLOGY 116/191 ; ONCOLOGY 113/241 |
| 39 | Yen CC, Yang YH, Ku HY, Hu HM, Lo SS, Chang HC, Chao Y, Chen JS, Wang HP, Wang TE, Bai LY, Wu MS, Yen CJ, Chen LT, Shan YS. The impact of preoperative waiting time in Stage II-III gastric or gastroesophageal junction cancer: A population-based cohort study Cancer Med Aug 1. IF:4 / Ranking:ONCOLOGY 96/241 |
| 40 | Chang CH, Peng WY, Lee WH, Lin TY, Yang MH, Dalley JW, Tsai TH. Transfer and biotransformation of the COVID-19 prodrug molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-placenta barrier EBioMedicine Aug 4. IF:11.1 / Ranking:MEDICINE, RESEARCH & EXPERIMENTAL 10/136 |
| 41 | Chang YW, Hsiao HW, Chen JP, Tzeng SF, Tsai CH, Wu CY, Hsieh HH, Carmona SJ, Andreatta M, Di Conza G, Su MT, Koni PA, Ho PC, Chen HK, Yang MH. A CSF-1R-blocking antibody/IL-10 fusion protein increases anti-tumor immunity by effectuating tumor-resident CD8(+) T cells Cell Rep Med Aug 15. IF:14.3 / Ranking:CELL BIOLOGY 17/191; MEDICINE, RESEARCH & EXPERIMENTAL 5/136 |
| 42 | Chao TC, Tsai YF, Liu CY, Lien PJ, Lin YS, Feng CJ, Chen YJ, Lai JI, Hsu CY, Lynn JJ, Huang CC, Tseng LM. Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis Front Oncol Aug 15. IF:4.7 / Ranking:ONCOLOGY 85/241 |
| 43 | Chang CH, Peng WY, Lee WH, Lin TY, Yang MH, Dalley JW, Tsai TH. . Biotransformation and brain distribution of the anti-COVID-19 drug molnupiravir and herb-drug pharmacokinetic interactions between the herbal extract Scutellaria formula-NRICM101 J Pharm Biomed Anal. Sep 01. IF:3.4 / Ranking:CHEMISTRY, ANALYTICAL 30/86; PHARMACOLOGY & PHARMACY 126/277 |
| 44 | Chen CW, Ou TS, Chen WS, Jiang JK, Yang SH, Wang HS, Chang SC, Lan YT, Lin CC, Lin HH, Huang SC, Cheng HH, Yang YW, Lin YZ, Chao Y, Wang LW, Teng HW. Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability Clin Colorectal Cancer Sep 01. IF:3.4 / Ranking:ONCOLOGY 125/241 |
| 45 | Wu YH, Chao HS, Chiang CL, Luo YH, Chiu CH, Yen SH, Liu CY, Chiou JF, Burnouf T, Chen YJ, Wang PY, Chao TY, Hsu SM, Lu LS. Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell-derived organoids Thorac Cancer Sep 01. IF:2.9 / Ranking:ONCOLOGY 163/241; RESPIRATORY SYSTEM 43/65 |
| 46 | Liu CY. Understanding Gastric Adenosquamous Cell Carcinoma: Insights from Immunoprofiling J Chin Med Assoc Sep 01. IF:3 / Ranking:MEDICINE, GENERAL & INTERNAL 75/167 |
| 47 | Wang YH, Wu WC, Hsiao LT, Ma SH, Chen CC, Ho YH. Acquired hemophilia A in a Taiwanese patient with bullous pemphigoid Int J Rheum Dis Sep 01. IF:2.5 / Ranking:RHEUMATOLOGY 24/34 |
| 48 | Huang CC, Tsai YF, Liu CY, Lien PJ, Lin YS, Chao TC, Feng CJ, Chen YJ, Lai JI, Cheng HF, Chen BF, Hsu CY, Chiu JH, Tseng LM. Concordance of Targeted Sequencing from Circulating Tumor DNA and Paired Tumor Tissue for Early Breast Cancer Cancers (Basel) Sep 08. IF:5.2 / Ranking:ONCOLOGY 72/241 |
| 49 | Wu CE, Liao YH, Wu CL, Yen RF, Lin CC, Yang MH, Yen CC, Su WC, Yen CJ, Chang YF, Wu MF, Yang Y, Lin CY, Yang WC, Wang HC, Li CY, Ho YY, Chang YY, Wu CS, Hsu HC, Chen KH, Huang Y, Chen CJ, Chuang PJ, Lai YC, Huang YY, Tseng NC, Huang YT, Chu CY, Wen-Cheng Chang J. Clinical practice consensus for the diagnosis and management of melanoma in Taiwan J Formos Med Assoc Sep 08. IF:3.2 / Ranking:MEDICINE, GENERAL & INTERNAL 69/167 |
| 50 | Chen ZR, Chueh CH, Chiang NJ, Tsai YW. Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration Cost Eff Resour Alloc Sep 11. IF:2.3 / Ranking:HEALTH POLICY & SERVICES 59/87 |
| 51 | Chang CH, Cheng TY, Yeh WW, Luo YL, Campbell M, Kuo TC, Shen TW, Hong YC, Tsai CH, Peng YC, Pan CC, Yang MH, Shih JC, Kung HJ, Huang WJ, Chang PC, Lin TP. REST-repressed lncRNA LINC01801 induces neuroendocrine differentiation in prostate cancer via transcriptional activation of autophagy Am J Cancer Res Sep 15. IF:5.3 / Ranking:ONCOLOGY 70/241 |
| 52 | Chiu JWY, Lee SC, Ho JC, Park YH, Chao TC, Kim SB, Lim E, Lin CH, Loi S, Low SY, Teo LLS, Yeo W, Dent R. Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel Drug Saf Oct 1. IF:4.2 / Ranking:PHARMACOLOGY & PHARMACY 92/277; PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH 72/207; TOXICOLOGY 23/94 |
| 53 | Chang CH, Peng WY, Lee WH, Yang L, Lin TY, Yang MH, Tsai TH. Transporter modulation of molnupiravir and its metabolite β-D-N4-hydroxycytidine across the blood-brain barrier in a rat Commun Med (Lond) Oct 19. IF:N/A / Ranking:N/A |
| 54 | Wang SF, Lin YS, Yeh WY, Chang YL, Chiang CE, Chen CH, Tseng LM, Lee HC, Liu CY, Cheng HM. The Clinical Benefits of Antiresorptive Agents in Patients with Primary Breast Cancer Receiving Adjuvant Endocrine Therapy: A Systematic Review with Pairwise and Network Meta-analysis J Clin Endocrinol Metab Oct 18. IF:5.8 / Ranking:ENDOCRINOLOGY & METABOLISM 31/145 |
| 55 | Hou MH, Lee CY, Ho CY, Yu TY, Hung GY, Huang FL, Chiou TJ, Liu CY, Yen HJ. Donor Lymphocyte Infusion for Prophylaxis and Treatment of Relapse in Pediatric Hematologic Malignancies after Allogeneic Hematopoietic Stem Cell Transplant J Chin Med Assoc Nov 1. IF:3 / Ranking:MEDICINE, GENERAL & INTERNAL 75/167 |
| 56 | Chan PW, Yu H, Hsu CH, Liu CY. Characteristics of early short-term traditional Chinese medicine in breast cancer patients: A population-based cohort study J Chin Med Assoc Nov 14. IF:3 / Ranking:MEDICINE, GENERAL & INTERNAL 75/167 |
| 57 | Huang SC, Chang SC, Liao TT, Yang MH. Detection and clinical significance of CEACAM5 methylation in colorectal cancer patients Cancer Sci Nov 9. IF:5.7 / Ranking:ONCOLOGY 62/241 |
| 58 | Lai JI, Kuo TH, Huang KJ, Chai LMX, Lee MH, Liu CY, Tsai YF, Huang CC, Tseng LM, Hsu CC, Chao TC. Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients Oncologist Nov 23. IF:5.8 / Ranking:ONCOLOGY 78/318 |
| 59 | Liu MT, Liang SY, Chao TC, Tseng LM, Rosenberg J. The Behavioral Adaptations and Barriers of Patients Employing Non-Pharmacological Strategies for Cancer Pain Management-A Qualitative Study Healthcare (Basel) Nov 7. IF:2.8 / Ranking:HEALTH CARE SCIENCES & SERVICES 57/106; HEALTH POLICY & SERVICES 43/87 |
| 60 | Mai HQ, Chen QY, Chen D, Hu C, Yang K, Wen J, Li J, Shi Y, Jin F, Xu R, Pan J, Qu S, Li P, Hu C, Liu YC, Jiang Y, He X, Wang HM, Lim WT, Liao W, He X, Chen X, Wang S, Yuan X, Li Q, Lin X, Jing S, Chen Y, Lu Y, Hsieh CY, Yang MH, Yen CJ, Samol J, Luo X, Wang X, Tang X, Feng H, Yao S, Keegan P, Xu RH. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial Jama Nov 28. IF:120.7 / Ranking:MEDICINE, GENERAL & INTERNAL 3/169 |
| 61 | Chang GC, Chiu CH, Yu CJ, Chang YC, Chang YH, Hsu KH, Wu YC, Chen CY, Hsu HH, Wu MT, Yang CT, Chong IW, Lin YC, Hsia TC, Lin MC, Su WC, Lin CB, Lee KY, Wei YF, Lan GY, Chan WP, Wang KL, Wu MH, Tsai HH, Chian CF, Lai RS, Shih JY, Wang CL, Hsu JS, Chen KC, Chen CK, Hsia JY, Peng CK, Tang EK, Hsu CL, Chou TY, Shen WC, Tsai YH, Tsai CM, Chen YM, Lee YC, Chen HY, Yu SL, Chen CJ, Wan YL, Hsiung CA, Yang PC; TALENT Investigators.. Low-dose CT screening among never-smokers with or without a family history of lung cancer in Taiwan: a prospective cohort study Lancet Respir Med Nov 29. IF:76.2 / Ranking:CRITICAL CARE MEDICINE 1/35; RESPIRATORY SYSTEM 1/66 |
| 62 | Tseng LM, Huang CC, Tsai YF, Chen JL, Chao TC, Lai JI, Lien PJ, Lin YS, Feng CJ, Chen YJ, Chiu JH, Hsu CY, Liu CY. Correlation of an immune-related 8-gene panel with pathologic response to neoadjuvant chemotherapy in patients with primary breast cancers Transl Oncol Dec 01. IF:5 / Ranking:ONCOLOGY 77/241 |
| 63 | Chen TW, Dai MS, Tseng LM, Chen SC, Chao TY, Chao TC, Chang YC, Chiu CF, Liu CT, Lin CH, Liu CY, Chen YF, Chang DY, Yu JC, Rau KM, Hsieh YY, Shen SC, Huang SM, Cheng AL, Lu YS.. Whole-Brain Radiotherapy Alone vs Preceded by Bevacizumab, Etoposide, and Cisplatin for Untreated Brain Metastases From Breast Cancer: A Randomized Clinical Trial JAMA Oncol Dec 21. IF:28.4 / Ranking:ONCOLOGY 11/241 |
| 64 | Cheng HF, Tsai YF, Liu CY, Hsu CY, Lien PJ, Lin YS, Chao TC, Lai JI, Feng CJ, Chen YJ, Chen BF, Chiu JH, Tseng LM, Huang CC.. Prevalence of BRCA1, BRCA2, and PALB2 genomic alterations among 924 Taiwanese breast cancer assays with tumor-only targeted sequencing: extended data analysis from the VGH-TAYLOR study Breast Cancer Res Dec 14. IF:7.4 / Ranking:ONCOLOGY 43/241 |
| 65 | Chen BF, Tsai YF, Lien PJ, Lin YS, Feng CJ, Chen YJ, Cheng HF, Liu CY, Chao TC, Lai JI, Tseng LM, Huang CC. . Prevalent landscape of tumor genomic alterations of luminal B1 breast cancers using a comprehensive genomic profiling assay in Taiwan Breast Cancer Dec 09. IF:4 / Ranking:OBSTETRICS & GYNECOLOGY 17/85; ONCOLOGY 96/241 |
| 66 | Ho IW, Pan YL, Lai JI, Liu CY.. Characteristics and outcome of systemic treatment for metastatic or unresectable thymic carcinoma: A single institution experience Thorac Cancer Dec 27. IF:2.9 / Ranking:ONCOLOGY 163/241; RESPIRATORY SYSTEM 43/65 |
| 67 | Su YY, Chiang NJ, Chiu TJ, Huang CJ, Hsu SJ, Lin HC, Yang SH, Yang Y, Chou WC, Chen YY, Bai LY, Li CP, Chen JS.. Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation Biomed J Dec 31. IF:5.5 / Ranking:BIOCHEMISTRY & MOLECULAR BIOLOGY 70/285; MEDICINE, RESEARCH & EXPERIMENTAL 38/136 |
| 68 | Tobias J, Högler S, Raigel M, Lin DS, Chao Y, Kenner L, Garner-Spitzer E, Yavrom S, Ede NJ, Zielinski CC, Kundi M, Wiedermann U. . Preclinical and Clinical Observations Implying Combination Therapy to Enhance the Efficacy of the Her-2/neu B-Cell Peptide-Based Vaccine HER-Vaxx and to Prevent Immune Evasion Int J Mol Sci Dec 24. IF:5.6 / Ranking:BIOCHEMISTRY & MOLECULAR BIOLOGY 66/285; CHEMISTRY, MULTIDISCIPLINARY 52/178 |
最後更新：